1920px-hiv-budding-color

Scientists use duoCAR-T therapy to fight HIV

pharmafile | August 9, 2019 | News story | Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma 

Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy is effective against HIV in human mouse models.

According to a paper published in the journal Science Translation Medicine, the scientists were able to use ‘duoCAR-T cells’, which use two CAR molecules, to supress HIV.  

The researchers found that the duoCAR-T cells were able to control HIV in mice and believe that the therapy may one day be used to eradicate HIV in humans in raiding the reservoirs of dormant infected immune cells that cannot be targeted using traditional antiretroviral drugs.

Advertisement

Previously, when researchers have tested CAR-T therapies against HIV, they have found the CAR-T cells themselves become infected with virus.

However, in doubling up on the chimeric antigen receptor molecules, the duoCAR-T cells were able to effectively fight HIV. The therapy eliminated 99% of infected immune cells in vitro and 97% of cells in mice. The duoCAR-T cells were also resistant to being infected with HIV.

Now, clinical trials aimed at testing the safety and effectiveness of the approach are scheduled for next Spring.

Louis Goss

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

European Commission approves HIV prevention injection

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …

CuraCell granted approval for trial of new therapy for metastatic cancers

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a …

The Gateway to Local Adoption Series

Latest content